DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.
DS8201-A-U305
Phase 3 small_molecule active
Quick answer
DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion. for High-Risk HER2-Positive Breast Cancer is a Phase 3 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- High-Risk HER2-Positive Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active